This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Primary Hyperoxaluria Type 1
  • /
  • A Study to Evaluate Lumasiran in Patients With Adv...
Clinical trial

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

Read time: 1 mins
Last updated:16th Nov 2020
Status: Recruiting
Identifier: NCT04152200
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)


The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).


Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)
Actual Study Start Date: January 21, 2020
Estimated Primary Completion Date: May 2021
Estimated Study Completion Date: July 2025

Arm:
- Experimental: Lumasiran

Category Value
Study type(s) Interventional
Expected enrolment 20
Actual Study start date 21 January 2020
Estimated Study Completion Date 01 July 2025

View full details